Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate.
The results of treatment with D-penicillamine (D-P) or zinc sulphate (Zn) in 67 newly diagnosed cases of Wilson's disease have been compared. All patients (7 with hepatic, 1 with psychiatric and 59 with neurological or preclinical forms) were fully compliant. During 12 years of observation, 34 patients received d-P and 33 Zn as the primary treatment. Fifteen patients (44%) discontinued D-P, in 10 cases owing to side effects. Four (12%) patients discontinued Zn, in 2 cases because of side-effects. One patient who received Zn deteriorated during the first few months after the initiation of therapy. The effectiveness of long-term treatment with D-P and Zn was similar in those patients who were able to continue the initial therapy. Zn was tolerated better than D-P; we suggest, therefore, that it may be recommended as an initial therapy for patients in the preclinical stage of Wilson's disease or with neurological presentation of the disease. More observation is needed for patients with the hepatic and psychiatric forms of the disease.
Czlonkowska
A
A
2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Gajda
J
J
Rodo
M
M
D000328:Adult; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D010349:Patient Compliance; D010396:Penicillamine / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D019287:Zinc Sulfate / Q000627:therapeutic use*
D019287:Zinc Sulfate; D010396:Penicillamine